Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus and Bortezomib in Relapsed/Refractory Multiple Myeloma
NCT00483262Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2007
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in multiple myeloma (MM), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Number of Patients With Specific Toxicities at 10 months and Best Response to Combination Treatment at 10 months. Started May 2007; status: completed.
02
Drugs
temsirolimus
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00483262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483262.